DMK
REGN icon

David M. Knott’s Regeneron Pharmaceuticals REGN Stock Holding History

David M. Knott’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3.63M Hold
6,000
– – 1.32% 20
2021
Q2 		$3.35M Buy
+6,000
New +$3.04M 1.19% 22

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

David M. Knott's REGN Position: Q3 2021 in Review

David M. Knott held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2021 at 6,000 shares worth $3.63M. The position accounts for 1.32% of the portfolio, ranked #20.

David M. Knott first reported a position in REGN in Q2 2021 and has held it in 2 quarters since. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • David M. Knott held 6,000 shares of Regeneron Pharmaceuticals worth $3.63M as of Q3 2021.
  • David M. Knott left its Regeneron Pharmaceuticals share count unchanged in Q3 2021.
  • Regeneron Pharmaceuticals made up 1.32% of David M. Knott's portfolio in Q3 2021, its #20 holding.
  • David M. Knott first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.